The value: why localisation pays off across global trials
June 26, 2026 | Localisation, clinical trials, translation
Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.
In our first two articles, we looked at where translation falls short and what good localisation actually looks like. Now we come to the part that affects timelines, budgets and trial delivery: the operational impact of getting localisation wrong.
Poor localisation rarely announces itself. It shows up quietly, in extra questions, slower processes, and avoidable rework. Strong localisation does the opposite. It keeps trials moving and helps sites focus on participants.
Where poor localisation creates friction
When materials don’t quite land, the effects ripple across sites and regions. Teams often see more site queries, with participants asking staff to explain content that should already be clear. Consent and onboarding slow down as confusion delays decisions. And when materials need revising market by market after launch, rework quickly builds.
These aren’t isolated problems. In our recent report The Site Factor, 27% of European respondents cited delays in receiving sponsor materials as their biggest barrier to enrolling participants. Just 24% of site teams say they use sponsor-provided materials, while others supplement them with their own materials or report having no participant-facing materials at all.
The hidden cost of fixing content late
Fixing localisation late is far more expensive than getting it right early. A single change to a master document can trigger updates across every language version, requiring fresh review, approval and redistribution. When amendments arrive out of sequence, sites are left unsure what to apply and when.
That uncertainty has a cost. It pulls site staff away from participants, adds review cycles, and risks inconsistency across regions. The later you spot the gap, the wider it spreads.
How strong localisation supports smoother delivery
Done well, localisation removes friction before it starts. Content arrives ready to use, reducing the burden on site teams to interpret, adapt or explain materials that participants find difficult to understand.
Across a trial, those benefits add up: fewer clarification queries for site staff, more consistent understanding across markets, smoother consent and onboarding processes, and less need for local workarounds or supplementary materials.
When participants understand what’s being asked of them, they’re more likely to engage and stay. And a better participant experience links directly to greater study completion.
Localisation, risk and diversity
Localisation isn’t just about clarity. It’s about reach. If your materials only work for some communities, your trial only reaches those communities. That limits diversity and skews representation, ultimately affecting the quality of the data generated.
Strong localisation helps you recruit fairly across regions and cultures. It reduces protocol misunderstandings, supports adherence, and lowers the risk of avoidable delays. In short, it makes trials more efficient and more representative.
Bringing the series together
Across these three articles, one idea has stayed constant. While translation carries the language, localisation carries the meaning.
That difference shapes how participants interpret, trust and engage with your trial. Treat localisation as a core part of your trial communication strategy, not a final production step, and you’ll see the value in smoother delivery, stronger engagement and better outcomes for everyone involved.
And that’s a goal worth building towards.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
From text to context: Helping patients see side effects clearly
Discover how thoughtful design, clear language, and structured visuals can transform overwhelming side effect information into accessible, actionable insights for patients in our latest Health Literacy series.
Why patient engagement must come first in rare disease trials
Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients’ lives to build trust and improve outcomes.
New Cuttsy+Cuttsy research shows why site support matters more than ever
Cuttsy+Cuttsy’s upcoming report, ‘The site factor: Where protocol meets practice in clinical trials’, delves into the critical role of site staff in clinical research, offering insights into their daily challenges,…
Cuttsy+Cuttsy becomes employee owned
Cuttsy+Cuttsy announces its transition to employee ownership, celebrating 15 years of prioritising clients, patients, and its team while continuing under the leadership of founders Caroline Benson and Mathew Cutts.
Clinical research in 2026: The trends shaping tomorrow
Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.
From overwhelming to actionable: Bringing lifestyle guidance to life
Discover how clear communication and health literacy principles can transform complex patient materials into simple, engaging, and empowering health information.
Behind the scenes: why we created ‘The participation equation’
Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research.
Cuttsy+Cuttsy launches R:SQD – a new way to predict and improve trial success
Cuttsy+Cuttsy has launched R:SQD, an innovative recruitment and retention success scoring tool that helps clinical trial sponsors predict, measure, and improve participant engagement and trial outcomes.
New report, The participation equation, uncovers key drivers of patient engagement in clinical trials
Cuttsy+Cuttsy’s new report, The participation equation, uncovers what drives patient engagement and retention in modern clinical trials through insights from over 700 participants and industry experts.
Why patients drop out of weight management trials and what you can do about it
Discover the key barriers to retention in obesity and weight-management trials and explore actionable, patient-centered strategies to improve engagement, outcomes, and data reliability.